ImugeneIUGNF PB Ratio is 1.02 as of Jun. 26, 2026. The stock has 4 warning signs investors should review. Among 1,232 Biotechnology companies, Imugene ranks better than 88.47% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), Imugene's share price is $0.09. Imugene's Book Value per Share for the quarter that ended in Dec. 2025 was $0.09. Hence, Imugene's PB Ratio of today is 1.02.
The historical rank and industry rank for Imugene's PB Ratio or its related term are showing as below:
IUGNF'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.87
Current: 0.82
During the past 13 years, Imugene's highest PB Ratio was 0.87. The lowest was 0.00. And the median was 0.00.
IUGNF's PB Ratio is ranked better than 88.47% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs IUGNF: 0.82
During the past 12 months, Imugene's average Book Value Per Share Growth Rate was -54.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -36.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -8.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 13.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Imugene was 46.30% per year. The lowest was -79.20% per year. And the median was -10.60% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Imugene PB Ratio Related Terms
Imugene PB Ratio Historical Data
* Premium members only.
The historical data trend for Imugene's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Imugene's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imugene PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Imugene's PB Ratio distribution charts can be found below:
* The bar in red indicates where Imugene's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Imugene's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Imugene (IUGNF) has a PB Ratio of 1.02 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Imugene and its competitors. According to the industry distribution chart, Imugene ranks #142 out of 1232 companies in the Biotechnology industry, placing it in the top 11.5%.
Is Imugene's PB Ratio too high?
Imugene's current PB Ratio is 1.02. The Biotechnology industry median PB Ratio is 2.80. Imugene's value of 1.02 is 63.6% below this industry median. Based on the distribution chart, Imugene ranks #142 out of 1232 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Imugene's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Imugene ranks #142 out of 1232 companies for PB Ratio. This places Imugene in the top 12% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.80. Imugene's value of 1.02 is 63.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Imugene's current PB Ratio of 1.02 is 63.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Imugene and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imugene's current PB Ratio is 1.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imugene stock overvalued right now?
Imugene (IUGNF) has a current PB Ratio of 1.02. The current PB Ratio is 1.02 and 63.6% below the Biotechnology industry median of 2.80. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Imugene (IUGNF), the current PB Ratio is 1.02 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Imugene Ltd is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IUGNF has been successfully added to your 